GoKawiilTakeda's narcolepsy drug Orzeyful sparks research into orexin agonists for other conditions
Following the August approval of Takeda's narcolepsy treatment Orzeyful (oveporexton), researchers are investigating whether orexin agonists could treat conditions beyond sleep disorders, including ADHD and other attention-related disorders. Takeda R&D president Andrew Plump compared the drug class's potential trajectory to GLP-1 drugs like Ozempic, which expanded from diabetes treatment into other therapeutic areas. The excitement builds on decades of research into orexins, brain peptides that influence sleep, mood, appetite and memory, first identified by scientists including Stanford's Luis de Lecea in the 1990s.
GoKawiil's interpretation of the reporting above, not reported fact.
If orexin agonists follow a GLP-1-like expansion path, it could open a substantial new market for Takeda and other drugmakers beyond the relatively narrow narcolepsy patient population, though this remains speculative at an early research stage. The comparison to GLP-1 drugs, which became blockbusters for weight loss and other uses, suggests investors and pharmaceutical companies may increasingly scrutinize this drug class for broader applications. Any expansion into ADHD or attention-related disorders would require substantial additional clinical research and regulatory approval before reaching patients.
- Takeda's Orzeyful (oveporexton) for narcolepsy was approved by US regulators in August
- Researchers are exploring orexin agonists for ADHD and other attention/alertness disorders
- Takeda's R&D chief draws an explicit comparison to GLP-1 drugs' expansion beyond diabetes
Source: nature.com — Heidt, 2026-10-20
Published there as: “Will this sleep-disorder drug be the next big blockbuster?”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.